Target, across the briefings
KMT2D across 4 cancers
KMT2D is on the target list of 4 of the briefings. No drug aimed at it carries an FDA label naming any of them.
| Disease | Label status | Furthest stage (Open Targets) | Distinct drugs | Cell-therapy trials |
|---|---|---|---|---|
| Anal cancer | no drug | 0 | — | |
| Diffuse large B-cell lymphoma | no drug | 0 | — | |
| Follicular lymphoma | no drug | 0 | — | |
| Medulloblastoma | no drug | 0 | — |
"Approved here" means a drug Open Targets records as aimed at KMT2D carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov.